Biomarkers for diagnosis of the vulnerable atherosclerotic plaque

Interventional Cardiology

Volumn 3, Issue 2, 2011, Pages 223-233

  Giannakopoulos, Triantafillos G ^a   Avgerinos, Efthimios D ^a   Moulakakis, Konstantinos G ^a   Kadoglou, Nikolaos P ^a   Preza, Ourania ^a   Papapetrou, Anastasios ^a   Papasideris, Christos ^a   Liapis, Christos D ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

atherosclerosis; biomarkers; vulnerable plaque

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CD40 ANTIGEN; FIBRINOGEN; GELATINASE B; INTERLEUKIN 18; INTERLEUKIN 6; MATRILYSIN; MYELOPEROXIDASE; NEUTROPHIL COLLAGENASE; TUMOR NECROSIS FACTOR ALPHA;

ATHEROSCLEROTIC PLAQUE; BLOOD SAMPLING; CAROTID ARTERY DISEASE; CEREBRAL ARTERY DISEASE; DIAGNOSTIC ACCURACY; DISEASE COURSE; HUMAN; ISCHEMIC HEART DISEASE; LEUKOCYTE COUNT; NONHUMAN; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

EID: 79955758142     PISSN: 17555302     EISSN: 17555310     Source Type: Journal    
DOI: 10.2217/ica.11.11     Document Type: Review

References (120)

1. Naghavi M, Libby P, Falk E et al.: From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: part I. Circulation 108, 1664-1672 (2003). (Pubitemid 37243650)
2. Becker RC: Emerging paradigms, platforms, and unifying themes in biomarker science. J. Am. Coll. Cardiol. 50(18), 1777-1780 (2007).
3. Thomas JC, Vohra RS, Beer S et al.: Biomarkers in peripheral arterial disease. Trends Cardiovasc. Med. 19, 147-151 (2009).
4. Yazdani SK, Vorpahl M, Ladich E, Virmani R: Pathology and vulnerability of atherosclerotic plaque: identification, treatment options, and individual patient differences for prevention of stroke. Curr. Treat. Options Cardiovasc. Med. 12(3), 297-314 (2010).
5. Thim T, Hagensen MK, Bentzon JF, Falk E: From vulnerable plaque to atherothrombosis. J. Intern. Med. 263(5), 506-516 (2008). (Pubitemid 351545740)
6. Shalhoub J, Owen DR, Gauthier T, Monaco C, Leen EL, Davies AH: The use of contrast enhanced ultrasound in carotid arterial disease. Eur. J. Vasc. Endovasc. Surg. 39(4), 381-387 (2010).
7. Liapis CD: Role of risk factors. In:Rutherford's Vascular Surgery (7th Edition). Cronenwett JL, Johnston KW (Eds). Elsevier Publishing, PA, USA, 8211 (2010)
8. Holtzman JL: Atherosclerosis and oxidant stress, a new perspective. Springer Science and Business Media, LLC, PA, USA (2008).
9. Williams KJ, Tabas I: The response-to-retention hypothesis of early atherogenesis. Arterioscler. Thromb. Vasc. Biol. 15, 551-561 (1995).
10. Flavahan NA: Atherosclerosis or lipoprotein induced endothelial dysfunction: potential mechanisms underlying reduction in EDRF/ nitric oxide activity. Circulation 85, 1927-1938 (1992).
11. Cybulsky MI, Gimbrone MAJ: Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. Science 251(4995), 788-7891 (1991).
12. Berliner JA, Navab M, Fogelman AM et al.: Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics. Circulation 91(9), 2488-2496 (1995).
13. Tsao PS, Buitrago R, Chan JR et al.: Fluid flow inhibits endothelial adhesiveness: nitric oxide and transcriptional regulation of VCAM-1. Circulation 94(7), 1682-1689 (1996). (Pubitemid 26320275)
14. Tsao PS, Wang B, Buitrago R et al.: Nitric oxide regulates monocyte chemotactic protein-1. Circulation 96(3), 934-940 (1997). (Pubitemid 27329631)
15. Ross R: Cellular and molecular studies of atherosclerosis. Atherosclerosis 131, S3-S4 (1997).
16. Berliner JA, Territo MC, Sevanian A et al.: Minimally modified low density lipoprotein stimulates monocyte endothelial interactions. J. Clin. Invest. 85, 1260-1266 (1990). (Pubitemid 20123772)
17. Ross R: Cell biology of atherosclerosis. Annu. Rev. Physiol. 57, 791-804 (1995).
18. Doran AC, Meller N, McNamara CA: Role of smooth muscle cells in the initiation and early progression of atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 28(5), 812-819 (2008). (Pubitemid 351544093)
19. Stary HC: Natural history and histological classification of atherosclerotic lesions: an update. Arterioscler. Thromb. Vasc. Biol. 20(5), 1177-1178 (2000). (Pubitemid 30262913)
20. Golledge J, Greenhalgh RM, Davies AH: The symptomatic carotid plaque. Stroke 31(3), 774-781 (2000). (Pubitemid 30131669)
21. Hansson GK: Inflammation, atherosclerosis, and coronary artery disease. N. Engl. J. Med. 352(16), 1685-1695 (2005).
22. Daskalopoulou SS, Daskalopoulos ME, Perrea D et al.: Carotid artery atherosclerosis: what is the evidence for drug action? Curr. Pharm. Des. 13(11), 1141-1159 (2007). (Pubitemid 46739341)
23. Falk E: Why do plaques rupture? Circulation 86(6 Suppl.), III30-III42 (1992).
24. Davies JR, Rudd JF, Fryer TD et al.: Targeting the vulnerable plaque: the evolving role of nuclear imaging. J. Nucl. Cardiol. 12, 234-246 (2005). (Pubitemid 40450776)
25. Rosner D, Stoneman V, Littlewood T et al.: Interferon-g induces Fas trafficking and sensitization to apoptosis in vascular smooth muscle cells via a PI3K- and Akt-dependent mechanism. Am. J. Pathol. 168, 2054-2063 (2006). (Pubitemid 43825323)
26. Defraigne JO: Pathophysiology of atherosclerosis. In:Vascular Surgery, European Manual of Medicine Series . Liapis CD, Balzer K, Fernandes e Fernandes J et al. (Eds). Springer-Verlag, Berlin, Heidelberg, Germany, 23-25 (2007)
27. Volanakis JE: Human C-reactive protein: expression, structure, and function. Mol. Immunol. 38(2-3), 189-197 (2001). (Pubitemid 32786776)
28. Pietila K, Harmoinen A, Hermens W et al.: Serum C-reactive protein and infarct size in myocardial infarct patients with a closed versus an open infarct-related coronary artery after thrombolytic therapy. Eur. Heart J. 14(7), 915-919 (1993). (Pubitemid 23238809)
29. Buffon A, Liuzzo G, Biasucci LM et al.: Preprocedural serum levels of C-reactive protein predict early complications and late restenosis after coronary angioplasty. J. Am. Coll. Cardiol. 34, 1512-1521 (1999). (Pubitemid 29528666)
30. Paffen E, Vos HL, Bertina RM: C-reactive protein does not directly induce tissue factor in human monocytes. Arterioscler. Thromb. Vasc. Biol. 24(5), 975-981 (2004). (Pubitemid 38620881)
31. Giannakis E, Male DA, Ormsby RJ et al.: Multiple ligand binding sites on domain seven of human complement factor H. Int. Immunopharmacol. 1(3), 433-443 (2001). (Pubitemid 32197542)
32. Venugopal SK, Devaraj S, Yuhanna I et al.: Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation 106(12), 1439-1441 (2002).
33. Verma S, Kuliszewski MA, Li SH et al.: C-reactive protein attenuates endothelial progenitor cell survival, differentiation, and function: further evidence of a mechanistic link between C-reactive protein and cardiovascular disease. Circulation 109, 2058-2067 (2004). (Pubitemid 38620212)
34. Wang CH, Li SH, Weisel RD et al.: C-reactive protein upregulates angiotensin type 1 receptors in vascular smooth muscle. Circulation 107, 1783-1790 (2003). (Pubitemid 36418360)
35. Pasceri V, Chang J, Willerson JT et al.: Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation 103(21), 2531-2534 (2001). (Pubitemid 32521959)
36. Ridker PM, Cannon CP, Morrow D et al.: C-reactive protein levels and outcomes after statin therapy. N. Engl. J. Med. 352, 20-28 (2005). (Pubitemid 40075677)
37. Zaninotto M, Mion MM, Novello E et al.: New biochemical markers: from bench to bedside. Clin. Chim. Acta 381, 14-20 (2007). (Pubitemid 46719139)
38. Collet JP, Park D, Lesty C et al.: Influence of fibrin network conformation and fibrin fiber diameter on fibrinolysis speed: dynamic and structural approaches by confocal microscopy. Arterioscler. Thromb. Vasc. Biol. 20, 1354-1361 (2000). (Pubitemid 30262939)
39. Thompson SG, Keinast J, Pyke SDM et al.: For the European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N. Engl. J. Med. 332(10), 635-641 (1995).
40. Doweik L, Maca T, Schillinger M et al.: Fibrinogen predicts mortality in high risk patients with peripheral artery disease. Eur. J. Vasc. Endovasc. Surg. 26, 381-386 (2003). (Pubitemid 37266146)
41. Kofoed SC, Wittrup HH, Sillesen H et al.: Fibrinogen predicts ischaemic stroke and advanced atherosclerosis, but not echolucent, rupture-prone carotid plaques. Eur. Heart J. 24(6), 567-576 (2003). (Pubitemid 36343103)
42. Danesh J, Collins R, Appleby P et al.: Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA 279, 1477-1482 (1998). (Pubitemid 28228207)
43. Tzoulaki I, Murray GD, Lee AJ et al.: C-reactive protein, interleukin-6, and soluble adhesion molecules as predictors of progressive peripheral atherosclerosis in the general population: Edinburgh Artery Study. Circulation 112(7), 976-983 (2005). (Pubitemid 41170265)
44. Tzoulaki I, Murray GD, Price JF et al.: Hemostatic factors, inflammatory markers, and progressive peripheral atherosclerosis: the Edinburgh Artery Study. Am. J. Epidemiol. 163, 334-341 (2006). (Pubitemid 43238427)
45. McDermott MM, Guralnik JM, Corsi A et al.: Patterns of inflammation associated with peripheral arterial disease: the In CHIANTI study. Am. Heart J. 150, 276-281 (2005). (Pubitemid 41116253)
46. Allison MA, Criqui MH, McClelland RL et al.: The effect of novel cardiovascular risk factors on the ethnic-specific odds for peripheral arterial disease in the Multi-Ethnic Study of Atherosclerosis (MESA). J. Am. Coll. Cardiol. 48, 1190-1197 (2006). (Pubitemid 44345134)
47. Mallat Z, Corbaz A, Scoazec A et al.: Interleukin-18/interleukin-18 binding protein signaling modulates atherosclerotic lesion development and stability. Circ. Res. 89(7), E41-E45 (2001).
48. Elhage R, Jawien J, Rudling M et al.: Reduced atherosclerosis in interleukin-18 deficient apolipoprotein E-knockout mice. Cardiovasc. Res. 59, 234-240 (2003). (Pubitemid 36776389)
49. Mallat Z, Corbaz A, Scoazec A et al.: Expression of interleukin-18 in human atherosclerotic plaques and relation to plaque instability. Circulation 104(14), 1598-1603 (2001). (Pubitemid 32947520)
50. Young JL, Libby P, Schonbeck U: Cytokines in the pathogenesis of atherosclerosis. Thromb. Haemost. 88(4), 554-567 (2002). (Pubitemid 35173995)
51. Taubman MB, Fallon JT, Schecter AD et al.: Tissue factor in the pathogenesis of atherosclerosis. Thromb. Haemost. 78, 200-204 (1997). (Pubitemid 27289241)
52. André P, Nannizzi-Alaimo L, Prasad SK et al.: Platelet derived CD40L. The switch hitting player of cardiovascular disease. Circulation 106(8), 896-899 (2002). (Pubitemid 34925319)
53. Abedin M, Tintut Y, Demer LL: Vascular calcification: mechanisms and clinical ramifications. Arterioscler. Thromb. Vasc. Biol. 24(7), 1161-1170 (2004). (Pubitemid 38880003)
54. Johnson RC, Leopold JA, Loscalzo J: Vascular calcification: pathobiological mechanisms and clinical implications. Circ. Res. 99(10), 1044-1059 (2006). (Pubitemid 44729928)
55. O'Brien ER, Garvin MR, Stewart DK et al.: Osteopontin is synthesized by macrophage, smooth muscle, and endothelial cells in primary and restenotic human coronary atherosclerotic plaques. Arterioscler. Thromb. 14(10), 1648-1656 (1994).
56. Schoppet M, Preissner KT, Hofbauer LC: RANK ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function. Arterioscler. Thromb. Vasc. Biol. 22(4), 549-553 (2002). (Pubitemid 34408732)
57. Kiechl S, Schett G, Wenning G et al.: Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation 109(18), 2175-2180 (2004). (Pubitemid 38625393)
58. Jono S, Ikari Y, Shioi A et al.: Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation 106(10), 1192-1194 (2002). (Pubitemid 34988634)
59. Ohmori R, Momiyama Y, Taniguchi H et al.: Plasma osteopontin levels are associated with the presence and extent of coronary artery disease. Atherosclerosis 170(2), 333-337 (2003). (Pubitemid 37377807)
60. Kurata M, Okura T, Watanabe S et al.: Osteopontin and carotid atherosclerosis in patients with essential hypertension. Clin. Sci. (Lond), 111(5), 319-324 (2006). (Pubitemid 44690190)
61. Golledge J, McCann M, Mangan S et al.: Osteoprotegerin and osteopontin are expressed at high concentrations within symptomatic carotid atherosclerosis. Stroke 35(7), 1636-1641 (2004). (Pubitemid 38823639)
62. Nybo M, Johnsen SP, Dethlefsen C et al.: Lack of observed association between high plasma osteoprotegerin concentrations and ischemic stroke risk in a healthy population. Clin. Chem. 54, 1969-1974 (2008). (Pubitemid 352774029)
63. Kadoglou NPE, Gerasimidis T, Golemati S et al.: The relationship between serum levels of vascular calcification inhibitors and carotid plaque vulnerability. J. Vasc. Surg. 47(1), 55-62 (2008).
64. Kadoglou NP, Gerasimidis T, Moumtzouoglou A et al.: Intensive lipid-lowering therapy ameliorates novel inflammatory and calcification markers and GSM score in patients with carotid stenosis. Eur. J. Vasc. Endovasc. Surg. 35(6), 661-668 (2008). (Pubitemid 351680152)
65. Kadoglou NP, Liapis CD: Matrix metalloproteinases: contribution to pathogenesis, diagnosis, surveillance and treatment of abdominal aortic aneurysms. Curr. Med. Res. Opin. 20, 419-432 (2004). (Pubitemid 38525149)
66. Alvarez B, Ruiz C, Chacon P, Alvarez-Sabin J, Matas M: Serum values of metalloproteinase-2 and metalloproteinase-9 as related to unstable plaque and inflammatory cells in patients with greater than 70% carotid artery stenosis. J. Vasc. Surg. 40, 469-475 (2004). (Pubitemid 39165021)
67. Eldrup N, Gronholdt ML, Sillesen H, Nordestgaard BG: Elevated matrix metalloproteinase-9 associated with stroke or cardiovascular death in patients with carotid stenosis. Circulation 114, 1847-1854 (2006). (Pubitemid 44673360)
68. Libby P, Ridker PM, Hansson GK et al.: Inflammation in atherosclerosis: from pathophysiology to practice. J. Am. Coll. Cardiol. 54(23), 2129-2138 (2009).
69. Halim SA, Newby LK: Prognostic biomarkers in individuals with prevalent coronary heart disease. Dis. Markers 26(5-6), 265-271 (2009).
70. Dorweiler B, Torzewski M, Dahm M et al.: Subendothelial infiltration of neutrophil granulocytes and liberation of matrix-destabilizing enzymes in an experimental model of human neo-intima. Thromb. Haemost. 99(2), 373-381 (2008). (Pubitemid 351230969)
71. Lijnen HR: Metalloproteinases in development and progression of vascular disease. Pathophysiol. Haemost. Thromb. 33(5-6), 275-281 (2003-2004). (Pubitemid 40278695)
72. Galis ZS, Khatri JJ: Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ. Res. 90(3), 251-262 (2002). (Pubitemid 34633925)
73. Jefferis BJ, Whincup P, Welsh P et al.: Prospective study of matrix metalloproteinase-9 and risk of myocardial infarction and stroke in older men and women. Atherosclerosis 208, 557-563 (2010).
74. Heider P, Pelisek J, Poppert H, Eckstein HH: Evaluation of serum matrix metalloproteinases as biomarkers for detection of neurological symptoms in carotid artery disease. Vasc. Endovasc. Surg. 43, 551-560 (2009).
75. Kadoglou NP, Daskalopoulou SS, Perrea D, Liapis CD: Matrix metalloproteinases and diabetic vascular complications. Angiology 56(2), 173-189 (2005). (Pubitemid 40404472)
76. Fabunmi RP, Sukhova GK, Sugiyama S et al.: Expression of tissue inhibitor of metalloproteinases-3 in human atheroma and regulation in lesion-associated cells: a potential protective mechanism in plaque stability. Circ. Res. 83(3), 270-278 (1998). (Pubitemid 28371316)
77. Mallat Z, Gojova A, Marchiol-Fournigault C et al.: Inhibition of transforming growth factor-b signaling accelerates atherosclerosis and induces an unstable plaque phenotype in mice. Circ. Res. 89(10), 930-934 (2001). (Pubitemid 34627899)
78. Lutgens E, Gijbels M, Smook M, et al.: Transforming growth factor-b mediates balance between inflammation and fibrosis during plaque progression. Arterioscler. Thromb. Vasc. Biol. 22(6), 975-982 (2002). (Pubitemid 34655226)
79. Jiang X, Zeng HS, Guo Y et al.: The expression of matrix metalloproteinases-9, transforming growth factor-b1 and transforming growth factor-b receptor I in human atherosclerotic plaque and their relationship with plaque stability. Chin. Med. J. 117, 1825-1829 (2004). (Pubitemid 40074230)
80. Kadoglou NP, Daskalopoulou SS, Perrea D et al.: Matrix metalloproteinases and diabetic vascular complications. Angiology 56(2), 173-189 (2005). (Pubitemid 40404472)
81. Kadoglou NP, Liapis CD: Matrix metalloproteinases: contribution to pathogenesis, diagnosis, surveillance and treatment of abdominal aortic aneurysms. Curr. Med. Res. Opin. 20(4), 419-432 (2004). (Pubitemid 38525149)
82. Cipollone F, Fazia ML, Iezzi A et al.: Association between prostaglandin E receptor subtype EP4 overexpression and unstable phenotype in atherosclerotic plaques in human. Arterioscler. Thromb. Vasc. Biol. 25(9), 1925-1931 (2005). (Pubitemid 41243464)
83. Cipollone F, Fazia ML, Iezzi A et al.: Balance between PGD synthase and PGE synthase is a major determinant of atherosclerotic plaque instability in humans. Arterioscler. Thromb. Vasc. Biol. 24(7), 1259-1265 (2004). (Pubitemid 38880018)
84. Cipollone F, Fazia ML, Iezzi A et al.: Blockade of the angiotensin II type 1 receptor stabilizes atherosclerotic plaques in humans by inhibiting prostaglandin E2-dependent matrix metalloproteinase activity. Circulation 109(12), 1482-1488 (2004). (Pubitemid 38420175)
85. Cipollone F, Prontera C, Pini B et al.: Overexpression of functionally coupled cyclooxygenase-2 and prostaglandin E synthase in symptomatic atherosclerotic plaques as a basis of prostaglandin E(2)- dependent plaque instability. Circulation 104(8), 921-927 (2001). (Pubitemid 32778044)
86. Podrez EA, Schmitt D, Hoff HF et al.: Myeloperoxidase-generated reactive nitrogen species convert LDL into an atherogenic form in vitro. J. Clin. Invest. 103, 1547-1560 (1999).
87. Naruko T, Ueda M, Haze K et al.: Neutrophil infiltration of culprit lesions in acute coronary syndromes. Circulation 106, 2894-2900 (2002). (Pubitemid 35424738)
88. Buffon A, Biasucci LM, Liuzzo G et al.: Widespread coronary inflammation in unstable angina. N. Engl. J. Med. 347, 5-12. (2002). (Pubitemid 34728951)
89. Sugiyama S, Okada Y, Sukhova GK et al.: Macrophage myeloperoxidase regulation by granulocyte macrophage colony-stimulating factor in human atherosclerosis and implications in acute coronary syndromes. Am. J. Pathol. 158, 879-891 (2001). (Pubitemid 32221781)
90. Anderson JL, Adams CD, Antman EM et al.: ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction. Circulation 116, E148-E304 (2007).
91. Thygesen K, Alpert JS, White HD et al.: Universal definition ofmyocardial infarction. Circulation 116, 2634-2653 (2007).
92. Morrow DA, Cannon CP, Jesse RL et al.: National Academy of Clinical Biochemistry Laboratory Medicine Practice guidelines: clinical characteristics and utilization of biochemical markers in acute coronary syndromes. Circulation 115, E356-E375 (2007) (Pubitemid 46648624)
93. Meuwese MC, Stroes ES, Hazen SL et al.: Serum myeloperoxidase levels are associated with the future risk of coronary artery disease in apparently healthy individuals: the EPIC-Norfolk Prospective Population Study. J. Am. Coll. Cardiol. 50, 159-165 (2007). (Pubitemid 47002189)
94. Baldus S, Heeschen C, Meinertz T et al.: Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation 108, 1440-1445 (2003). (Pubitemid 37176448)
95. Mocatta TJ, Pilbrow AP, Cameron VA et al.: Plasma concentrations of myeloperoxidase predict mortality after myocardial infarction. J. Am. Coll. Cardiol. 49, 1993-2000 (2007). (Pubitemid 46734639)
96. Morrow DA, Sabatine MS, Brennan ML et al.: Concurrent evaluation of novel cardiac biomarkers in acute coronary syndrome: myeloperoxidase and soluble CD40 ligand and the risk of recurrent ischaemic events in TACTICS-TIMI 18. Eur. Heart J. 29, 1096-1102 (2008). (Pubitemid 351844877)
97. Brennan ML, Penn MS, Van Lente F et al.: Prognostic value of myeloperoxidase in patients with chest pain. N. Engl. J. Med. 349, 1595-1604 (2003). (Pubitemid 37288567)
98. Ringleb PA, Allenberg J, Bruckmann H et al.; SPACE Collaborative Group: 30 day results from the SPACE trial of stent-protected angioplasty versus carotid endarterectomy in symptomatic patients: a randomised non-inferiority trial. Lancet 368, 1239-1247 (2006).
99. Mas JL, Chatellier G, Beyssen B; EVA-3S Investigators: Endarterectomy versus stenting in patients with symptomatic severe carotid stenosis. N. Engl. J. Med. 355, 1660-1671 (2006). (Pubitemid 44583956)
100. Ederle J, Dobson J, Featherstone RL et al.; International Carotid Stenting Study Investigators: Carotid artery stenting compared with endarterectomy in patients with symptomatic carotid stenosis (International Carotid Stenting Study): an interim analysis of a randomised controlled trial. Lancet 375, 985-997 (2010).
101. Heider P, Poppert H, Wolf O et al.: Fibrinogen and high-sensitive C-reactive protein as serologic predictors for perioperative cerebral microembolic lesions after carotid endarterectomy. J. Vasc. Surg. 46, 449-454 (2007) (Pubitemid 47361635)
102. Gröschel K, Ernemann U, Larsen J et al.: Preprocedural C-reactive protein levels predict stroke and death in patients undergoing carotid stenting. Am. J. Neuroradiol. 28, 1743-1746 (2007). (Pubitemid 47598152)
103. Abe Y, Sakaguchi M, Furukado S et al.: Interleukin-6 release after carotid artery stenting and periprocedural new ischemic lesions. J. Cereb. Blood Flow Metab. 30, 857-863 (2010).
104. Aronow HD, Shishehbor M, Davis DA et al.: Leukocyte count predicts microembolic Doppler signals during carotid stenting. A link between inflammation and embolization. Stroke 36, 1910-1914 (2005). (Pubitemid 41266525)
105. Reiff T, Stingele R, Eckstein HH et al.: Stent-protected angioplasty in asymptomatic carotid artery stenosis vs. endarterectomy: SPACE2 - a three-arm randomised-controlled clinical trial. Int. J. Stroke 4, 294-299 (2009).
106. McDermott MM, Guralnik JM, Corsi A et al.: Patterns of inflammation associated with peripheral arterial disease: the InCHIANTI study. Am. Heart J. 150, 276-281 (2005). (Pubitemid 41116253)
107. Allison MA, Criqui MH, McClelland RL et al.: The effect of novel cardiovascular risk factors on the ethnic-specific odds for peripheral arterial disease in the Multi-Ethnic Study of Atherosclerosis (MESA). J. Am. Coll. Cardiol. 48, 1190-1197 (2006). (Pubitemid 44345134)
108. Libra M, Signorelli SS, Bevelacqua Y et al.: Analysis of G(-174)C IL-6 polymorphism and plasma concentrations of inflammatory markers in patients with Type 2 diabetes and peripheral arterial disease. J. Clin. Pathol. 59, 211-215 (2006). (Pubitemid 43235590)
109. Fiotti N, Giansante C, Ponte E et al.: Atherosclerosis and inflammation. Patterns of cytokine regulation in patients with peripheral arterial disease. Atherosclerosis 145, 51-60 (1999). (Pubitemid 29292700)
110. Danielsson P, Truedsson L, Eriksson KF, Norgren L: Inflammatory markers and IL-6 polymorphism in peripheral arterial disease with and without diabetes mellitus. Vasc. Med. 10, 191-198 (2005). (Pubitemid 41479673)
111. Ziegler S, Kudlacek S, Luger A, Minar E: Osteoprotegerin plasma concentrations correlate with severity of peripheral artery disease. Atherosclerosis 182, 175-180 (2005). (Pubitemid 41188384)
112. DePalma RG, Hayes VW, Cafferata HT et al.: Cytokine signatures in atherosclerotic claudicants. J. Surg. Res. 111, 215-221 (2003). (Pubitemid 36808912)
113. Nylaende M, Kroese A, Stranden E et al.: Markers of vascular inflammation are associated with the extent of atherosclerosis assessed as angiographic score and treadmill walking distances in patients with peripheral arterial occlusive disease. Vasc. Med. 11, 21-28 (2006).
114. Hoogeveen RC, Morrison A, Boerwinkle E et al.: Plasma MCP-1 level and risk for peripheral arterial disease and incident coronary heart disease: Atherosclerosis Risk in Communities Study. Atherosclerosis 183, 301-307 (2005). (Pubitemid 41579281)
115. Girn HR, Orsi NM, Homer-Vanniasinkam S: An overview of cytokine interactions in atherosclerosis and implications for peripheral arterial disease. Vasc. Med. 12, 299-309 (2007).
116. Tayebjee MH, Tan KT, MacFadyen RJ, Lip GY: Abnormal circulating levels of metalloprotease 9 and its tissue inhibitor 1 in angiographically proven peripheral arterial disease: relationship to disease severity. J. Intern. Med. 257, 110-116 (2005). (Pubitemid 40129132)
117. Fung ET, Wilson AM, Zhang F et al.: A biomarker panel forperipheral arterial disease. Vasc. Med. 13, 217-224 (2008).
118. Snyder N, Nguyen A, Gajula L et al.: The APRI may be enhanced by the use of the FIBROSpect II in the estimation of fibrosis in chronic hepatitis C. Clin. Chim. Acta 381, 119-23 (2007). (Pubitemid 46719149)
119. Paik S, Shak S, Tang G et al.: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med. 351, 2817-2826 (2004). (Pubitemid 40051905)
120. Wang TJ, Gona P, Larson MG et al.: Multiple biomarkers for the prediction of first major cardiovascular events and death. N. Engl. J. Med. 355, 2631-2639 (2006). (Pubitemid 44969122)